Assignee
CHROMADEX INC
US·13 granted patents·6 pending applications·22 citations·filing 2012–2025
Top patents by PatentIndex Score
19 records- 0188US10000520B2B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereofCHROMADEX INC·Filed 2017·Granted Jun 19, 2018·6 cites·9 claims
- 0286US10934322B2B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereofCHROMADEX INC·Filed 2018·Granted Mar 2, 2021·4 cites·18 claims
- 0384US10280190B2Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditionsCHROMADEX INC·Filed 2016·Granted May 7, 2019·6 cites·26 claims
- 0482US10183036B2Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursorsCHROMADEX INC·Filed 2017·Granted Jan 22, 2019·6 cites·8 claims
- 0574US12433908B2Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy developmentCHROMADEX INC·Filed 2022·Granted Oct 7, 2025·0 cites·13 claims
- 0673US11524022B2Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy developmentCHROMADEX INC·Filed 2020·Granted Dec 13, 2022·0 cites·22 claims
- 0770US10857172B2Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy developmentCHROMADEX INC·Filed 2017·Granted Dec 8, 2020·0 cites·10 claims
- 0867US11033568B2Nicotinamide riboside compositions for topical use in treating skin conditionsCHROMADEX INC·Filed 2020·Granted Jun 15, 2021·0 cites·16 claims
- 0967US10688118B2Nicotinamide riboside compositions for topical use in treating skin conditionsCHROMADEX INC·Filed 2014·Granted Jun 23, 2020·0 cites·6 claims
- 1066US2024415863A1Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereofCHROMADEX INC·Filed 2024·Application pending·0 cites
- 1164US12558367B2Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereofCHROMADEX INC·Filed 2025·Granted Feb 24, 2026·0 cites·14 claims
- 1262US2023295211A1Methods of producing crystalline beta nicotinamide riboside triacetate chlorideCHROMADEX INC·Filed 2023·Application pending·0 cites
- 1358US11214589B2Crystalline forms of nicotinoyl ribosides and derivatives thereof, and methods of preparation thereofCHROMADEX INC·Filed 2019·Granted Jan 4, 2022·0 cites·32 claims
- 1453US10039725B2Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbeneCHROMADEX INC·Filed 2014·Granted Aug 7, 2018·0 cites·22 claims
- 1553US2022241305A1Ethyl cellulose based coatings for microencapsulation of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivativesCHROMADEX INC·Filed 2022·Application pending·0 cites
- 1649US12485134B2Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulationsCHROMADEX INC·Filed 2020·Granted Dec 2, 2025·0 cites·11 claims
- 1738US2013149277A1Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disordersCHROMADEX INC·Filed 2012·Application pending·0 cites
- 1838US2013296440A1Pterostilbene and curcumin combination for treatment of oxidative stress and inflammationCHROMADEX INC·Filed 2013·Application pending·0 cites
- 1936US2016355539A1Selective solvent free phosphorylationCHROMADEX INC·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →